Nurix therapeutics presents updated positive data demonstrating durable, deepening responses in ongoing clinical trial of bexobrutideg (nx-5948) monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia (cll) and waldenstrÖm macroglobulinemia (wm)

Complete response achieved in cll; overall objective response rate of 80.9% in cll patients and 84.2% in patients with wm
WM Ratings Summary
WM Quant Ranking